Advertisement
UK markets close in 6 hours 18 minutes
  • FTSE 100

    7,818.53
    -58.52 (-0.74%)
     
  • FTSE 250

    19,264.45
    -186.22 (-0.96%)
     
  • AIM

    740.47
    -4.82 (-0.65%)
     
  • GBP/EUR

    1.1682
    -0.0001 (-0.01%)
     
  • GBP/USD

    1.2445
    +0.0007 (+0.05%)
     
  • Bitcoin GBP

    51,898.76
    +2,465.30 (+4.99%)
     
  • CMC Crypto 200

    1,331.84
    +19.21 (+1.46%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CRUDE OIL

    83.21
    +0.48 (+0.58%)
     
  • GOLD FUTURES

    2,400.10
    +2.10 (+0.09%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,666.91
    -170.49 (-0.96%)
     
  • CAC 40

    7,955.81
    -67.45 (-0.84%)
     

How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17

In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.